Physician profile
Ira Breite
NPI 1306830732
$5,680.04
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $851 · 2020: $500 · 2021: $926 · 2022: $1,660 · 2023: $1,686 · 2024: $57.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,743.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,242.43 | 2019-2024 | Skyrizi, Vraylar, Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $938.49 | 2019-2023 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $546.51 | 2019-2023 | |
| Janssen Biotech, INC. | $429.71 | 2019-2023 | Stelara |
| Celgene Corporation | $393.34 | 2021-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $324.23 | 2020-2023 | Entyvio |
| Qol Medical, LLC | $315.48 | 2019-2023 | Sucraid |
| Ironwood Pharmaceuticals, INC | $230.23 | 2019-2023 | Linzess |
| Ferring Pharmaceuticals INC. | $227.21 | 2019-2023 | Rebyota |
| Glaxosmithkline, LLC. | $222.20 | 2020-2024 | Shingrix, Arexvy |
| Lundbeck LLC | $181.74 | 2022-2023 | Rexulti |
| Pfizer INC. | $177.78 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $81.68 | 2022-2023 | Dupixent |
| Biohaven Pharmaceuticals, INC. | $80.81 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $63.75 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $54.54 | 2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $45.55 | 2022-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $38.97 | 2023 | |
| Shield Therapeutics INC | $30.85 | 2023 | Accrufer |
| Boston Scientific Corporation | $25.57 | 2020 | |
| Genzyme Corporation | $18.11 | 2022 | |
| Allergan, INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ira Breite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.